Clinical Scorecard: Decanoylcarnitine Enhances Fatty Acid β-Oxidation and Mitigates Mitochondrial Dysfunction in Liver Cells Infected with Hepatitis B Virus
At a Glance
Category
Detail
Condition
Chronic hepatitis B infection with associated metabolic dysfunction and mitochondrial impairment
Key Mechanisms
HBV infection impairs fatty acid β-oxidation and mitochondrial function; decanoylcarnitine supplementation activates CPT1A and PPARα pathways to restore metabolism
Target Population
Patients with chronic hepatitis B infection, especially those with metabolic-associated steatotic liver disease
Care Setting
Hepatology and infectious disease clinical settings managing chronic HBV infection and metabolic liver disease
Key Highlights
HBV infection causes fatty acid β-oxidation disorder and mitochondrial dysfunction in hepatocytes.
Decanoylcarnitine supplementation activates CPT1A expression and the PPARα signaling pathway, improving mitochondrial function and lipid metabolism.
Improvement of fatty acid metabolism via decanoylcarnitine offers a novel therapeutic approach for HBV-related liver mitochondrial dysfunction.
Guideline-Based Recommendations
Diagnosis
Assess mitochondrial function and fatty acid β-oxidation status in patients with chronic HBV infection and metabolic liver disease.
Management
Consider therapeutic strategies targeting fatty acid metabolism, such as decanoylcarnitine supplementation, to restore mitochondrial function in HBV-infected hepatocytes.
Upregulate CPT1A expression to improve mitochondrial β-oxidation and reduce lipid accumulation.
Monitoring & Follow-up
Monitor liver function and metabolic parameters to evaluate the efficacy of interventions targeting fatty acid metabolism and mitochondrial health.
Risks
Recognize that severe steatotic liver disease may impair antiviral therapy efficacy and increase risks of fibrosis and hepatocellular carcinoma.
Patient & Prescribing Data
Patients with chronic hepatitis B infection exhibiting metabolic-associated steatotic liver disease and mitochondrial dysfunction.
Exogenous decanoylcarnitine supplementation can partially restore impaired fatty acid metabolism and mitochondrial function by activating CPT1A and PPARα pathways.
Clinical Best Practices
Evaluate fatty acid β-oxidation and mitochondrial function in HBV-infected patients with metabolic liver disease.
Incorporate metabolic modulation therapies such as decanoylcarnitine to improve mitochondrial dysfunction.
Address metabolic dysfunction alongside antiviral treatment to reduce progression to fibrosis and hepatocellular carcinoma.
